Emylcamate
Jump to navigation
Jump to search
| File:Emylcamate.png | |
| Gene therapy | |
|---|---|
| Clinical data | |
| ATC code | |
| Physiological data | |
| Legal status | |
| Pharmacokinetic data | |
| Identifiers | |
| |
| CAS Number | |
| PubChem Template:Abbreviation | |
| Chemical and physical data | |
| Formula | C7H15NO2 |
| Molar mass | 145.20 g·mol−1 |
Emylcamate (marketed as Striatran® by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.
References
- Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia (Portuguese)
- The Comparative Toxicogenomics Database: Emylcamate.
- BIAM: Emylcamate (French).
Categories:
- Articles with short description
- Pages with broken file links
- Pages using infobox drug with unknown parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anxiolytics
- Muscle relaxants